NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
13.43
-0.80 (-5.66%)
Mar 6, 2026, 10:55 AM EST - Market open
NovoCure Revenue
In the year 2025, NovoCure had annual revenue of $655.35M with 8.28% growth. NovoCure had revenue of $174.35M in the quarter ending December 31, 2025, with 12.49% growth.
Revenue (ttm)
$655.35M
Revenue Growth
+5.41%
P/S Ratio
2.47
Revenue / Employee
$408,320
Employees
1,605
Market Cap
1.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 655.35M | 50.13M | 8.28% |
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -25.69M | -4.80% |
| Dec 31, 2021 | 535.03M | 286.96M | 115.68% |
| Dec 31, 2018 | 248.07M | 237.71M | 2,294.72% |
| Dec 31, 2013 | 10.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.24B |
| QuidelOrtho | 2.73B |
| Enovis | 2.25B |
| CONMED | 1.37B |
| Tandem Diabetes Care | 1.01B |
| Inspire Medical Systems | 911.98M |
| UFP Technologies | 602.80M |
| Artivion | 441.33M |
NVCR News
- 4 days ago - Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer - Business Wire
- 6 days ago - Novocure to Participate in 2026 Leerink Global Healthcare Conference - Business Wire
- 7 days ago - NovoCure Limited (NVCR) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update - Business Wire
- 10 days ago - Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer) - Business Wire
- 21 days ago - NovoCure: FDA Approval For PC Unlocked With TTFields Expansion Opportunity Approaching - Seeking Alpha
- 22 days ago - This Biotech Stock Is Jumping 25% After Getting an FDA Boost - Barrons
- 22 days ago - What's Happening With NovoCure Stock? - Forbes